Characterization and clinical impact of bloodstream infection caused by carbapenemase-producing enterobacteriaceae in seven Latin American countries

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Villegas, Maria Virginia ^a   Pallares, Christian J ^a,b   Escandón Vargas, Kevin ^a   Hernández Gómez, Cristhian ^a   Correa, Adriana ^a   Álvarez, Carlos ^c   Rosso, Fernando ^d   Matta, Lorena ^e   Luna, Carlos ^f   Zurita, Jeannete ^g   Mejía Villatoro, Carlos ^h   Rodríguez Noriega, Eduardo ⁱ   Seas, Carlos ^j   Cortesía, Manuel ^k   Guzmán Suárez, Alfonso ^l   Guzmán Blanco, Manuel ^l  

^a CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MÉDICAS CIDEIM   (Colombia)

^b Hospital Universario del Valle   (Colombia)

^c HOSPITAL UNIVERSITARIO SAN IGNACIO   (Colombia)

^d FUNDACIÓN VALLE DEL LILI   (Colombia)

^e PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^f HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^g PONTIFICIA UNIVERSIDAD CATÓLICA DEL ECUADOR   (Ecuador)

^h Roosevelt Hospital Guatemala   (Guatemala)

ⁱ HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^j HOSPITAL NACIONAL CAYETANO HEREDIA   (Peru)

^k Hospital de Clinicas Caracas   (Venezuela)

^l Centro Medico Docente La Trinidad   (Venezuela)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEM; CARBAPENEMASE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; DORIPENEM; ERTAPENEM; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN; POLYMYXIN B; RIFAMPICIN; SULBACTAM; TAZOBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE;

ADOLESCENT; ADULT; AGED; ARGENTINA; ARTICLE; BLAIMP GENE; BLAKPC GENE; BLANDM GENE; BLAOXA 48 GENE; BLAVIM GENE; BLOODSTREAM INFECTION; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CHILD; CLINICAL ASSESSMENT; COLOMBIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; ECUADOR; ENTEROBACTERIACEAE INFECTION; FEMALE; FOLLOW UP; GENE; GUATEMALA; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEXICO; MICROBIOLOGY; MORTALITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PERU; VENEZUELA; BIOSYNTHESIS; CLINICAL TRIAL; DRUG EFFECTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; NEWBORN; PATHOPHYSIOLOGY; PRESCHOOL CHILD; SEPSIS; SOUTH AND CENTRAL AMERICA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CHILD; CHILD, PRESCHOOL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LATIN AMERICA; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SEPSIS; YOUNG ADULT;

EID: 84977604914     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0154092     Document Type: Article

References (38)

1. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012; 25: 682-707. doi: 10.1128/CMR.05035-11 PMID: 23034326
2. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008; 29: 1099-1106. doi: 10.1086/592412 PMID: 18973455
3. Guh AY, Bulens SN, Mu Y, Jacob JT, Reno J, Scott J, et al. Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013. JAMA. 2015; 314: 1479-87. doi: 10.1001/jama. 2015.12480 PMID: 26436831
4. Nordmann P. Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge. Med Mal Infect. Elsevier Masson SAS; 2014; 44: 51-56. doi: 10.1016/j.medmal.2013.11.007
5. Maya JJ, Ruiz SJ, Blanco VM, Gotuzzo E, Guzman-Blanco M, Labarca J, et al. Current status of carbapenemases in Latin America. Expert Rev Anti Infect Ther. 2013; 11: 657-67. doi: 10.1586/14787210. 2013.811924 PMID: 23879607
6. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother. 2008; 52: 1028-1033. doi: 10.1128/AAC.01020-07 PMID: 18086836
7. Carmeli Y, Akova M, Cornaglia G, Daikos GL, Garau J, Harbarth S, et al. Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. Clin Microbiol Infect. 2010; 16: 102-111. doi: 10.1111/j.1469-0691.2009.03115.x PMID: 20085604
8. Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenemresistant Enterobacteriaceae infections. Emerg Infect Dis. 2014; 20: 1170-1175. doi: 10.3201/eid2007. 121004 PMID: 24959688
9. Kontopidou F, Giamarellou H, Katerelos P, Maragos A, Kioumis I, Trikka-Graphakos E, et al. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect. 2014; 20: O117-23. doi: 10.1111/1469-0691.12341 PMID: 23992130
10. Daikos GL, Markogiannakis A, Souli M, Tzouvelekis LS. Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective. Expert Rev Anti Infect Ther. 2012; 10: 1393-1404. doi: 10.1586/eri.12.138 PMID: 23253318
11. Hussein K, Raz-Pasteur A, Finkelstein R, Neuberger A, Shachor-Meyouhas Y, Oren I, et al. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae. J Hosp Infect. 2013; 83: 307-313. doi: 10.1016/j.jhin.2012.10.012 PMID: 23313086
12. Ben-David D, Kordevani R, Keller N, Tal I, Marzel A, Gal-Mor O, et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect. 2012; 18: 54-60. doi: 10. 1111/j.1469-0691.2011.03478.x
13. Borer A, Saidel-Odes L, Riesenberg K, Eskira S, Peled N, Nativ R, et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol. 2009; 30: 972-976. doi: 10.1086/605922 PMID: 19712030
14. Neuner EA, Yeh JY, Hall GS, Sekeres J, Endimiani A, Bonomo RA, et al. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis. 2011; 69: 357-362. doi: 10.1016/j.diagmicrobio.2010.10.013 PMID: 21396529
15. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: Importance of combination therapy. Clin Infect Dis. 2012; 55: 943-950. doi: 10.1093/cid/cis588 PMID: 22752516
16. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011; 17: 1798-1803. doi: 10.1111/j.1469-0691.2011.03514.x PMID: 21595793
17. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014; 58: 2322-2328. doi: 10.1128/AAC.02166-13 PMID: 24514083
18. de Oliveira MS, de Assis DB, Freire MP, Boas do Prado GV, Machado AS, Abdala E, et al. Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins. Clin Microbiol Infect. 2015; 21: 179.e1-7. doi: 10.1016/j.cmi.2014.07.010
19. Daikos GL, Petrikkos P, Psichogiou M, Kosmidis C, Vryonis E, Skoutelis A, et al. Prospective observational study of the impact of VIM-1 metallo-β-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother. 2009; 53: 1868-1873. doi: 10.1128/ AAC.00782-08 PMID: 19223638
20. Navarro-San Francisco C, Mora-Rillo M, Romero-Gómez MP, Moreno-Ramos F, Rico-Nieto A, Ruiz-Carrascoso G, et al. Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge. Clin Microbiol Infect. 2013; 19: E72-9. doi: 10.1111/1469-0691.12091 PMID: 23231088
21. Mouloudi E, Protonotariou E, Zagorianou A, Iosifidis E, Karapanagiotou A, Giasnetsova T, et al. Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect Control Hosp Epidemiol. 2010; 31: 1250-1256. doi: 10.1086/ 657135 PMID: 20973725
22. Jones RN, Guzman-Blanco M, Gales AC, Gallegos B, Leal Castro AL, Martino MDV, et al. Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011). Brazilian J Infect Dis. 2013; 17: 672-681. doi: 10.1016/j.bjid.2013.07.002
23. Hernández-Gómez C, Blanco VM, Motoa G, Correa A, Maya JJ, de la Cadena E, et al. Evolution of antimicrobial resistance in Gram negative bacilli from intensive care units in Colombia. Biomédica. 2014; 34: 91-100. PMID: 24968040
24. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/ SIS International Sepsis Definitions Conference. Crit Care Med. 2003; 31: 1250-1256. doi: 10.1097/01. CCM.0000050454.01978.3B PMID: 12682500
25. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol. 2009; 30: 1180-1185. doi: 10.1086/648451 PMID: 19860564
26. Pacheco R, Osorio L, Correa AM, Villegas MV. Prevalence of gram-negative bacteria harboring blaKPC gene in Colombian hospitals. Biomedica. 2014; 34: 81-90. PMID: 24968039
27. Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents. 1999; 11: 7-12. doi: 10.1016/S0924-8579(98)00060-0 PMID: 10075272
28. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing. CLSI M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
29. CDC / NHSN. Surveillance Definitions for Specific Types of Infections. 2014.
30. Doyle D, Peirano G, Lascols C, Lloyd T, Church DL, Pitout JD. Laboratory detection of Enterobacteriaceae that produce carbapenemases. J Clin Microbiol. 2012; 50: 3877-3880. doi: 10.1128/JCM.02117-12 PMID: 22993175
31. Rojas LJ, Mojica MF, Blanco VM, Correa A, Montealegre MC, De La Cadena E, et al. Emergence of Klebsiella pneumoniae coharboring KPC and VIM carbapenemases in Colombia. Antimicrob Agents Chemother. 2013; 57: 1101-1102. doi: 10.1128/AAC.01666-12 PMID: 23229478
32. Chow JW, Shlaes DM. Imipenem resistance associated with the loss of a 40 kDa outer membrane protein in Enterobacter aerogenes. J Antimicrob Chemother. 1991; 28: 499-504. doi: 10.1093/jac/28.4. 499 PMID: 1761444
33. MacKenzie FM, Forbes KJ, Dorai-John T, Amyes SGB, Gould JM. Emergence of a carbapenem- resistant Klebsiella pneumoniae. Lancet. 1997; 350: 783. PMID: 9298003
34. Tenover FC, Kalsi RK, Williams PP, Carey RB, Stocker S, Lonsway D, et al. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg Infect Dis. 2006; 12: 1209-1213. doi: 10.3201/eid1708.060291 PMID: 16965699
35. Tängdén T, Giske CG. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. J Intern Med. 2015; 277: 501-12. doi: 10.1111/joim.12342 PMID: 25556628
36. Falagas ME, Rafailidis PI, Kofteridis D, Virtzili S, Chelvatzoglou FC, Papaioannou V, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother. 2007; 60: 1124-1130. doi: 10.1093/jac/dkm356 PMID: 17884829
37. Ben-David D, Masarwa S, Navon-Venezia S, Mishali H, Fridental I, Rubinovitch B, et al. Carbapenemresistant Klebsiella pneumoniae in post-acute-care facilities in Israel. Infect Control Hosp Epidemiol. 2011; 32: 845-853. doi: 10.1086/661279 PMID: 21828964
38. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: Superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012; 56: 2108-2113. doi: 10.1128/AAC.06268-11 PMID: 22252816